Nothing Special   »   [go: up one dir, main page]

WO2006039532A3 - Transdermal therapeutic system for parkinson’s disease - Google Patents

Transdermal therapeutic system for parkinson’s disease Download PDF

Info

Publication number
WO2006039532A3
WO2006039532A3 PCT/US2005/035257 US2005035257W WO2006039532A3 WO 2006039532 A3 WO2006039532 A3 WO 2006039532A3 US 2005035257 W US2005035257 W US 2005035257W WO 2006039532 A3 WO2006039532 A3 WO 2006039532A3
Authority
WO
WIPO (PCT)
Prior art keywords
parkinson
disease
therapeutic system
transdermal therapeutic
tts
Prior art date
Application number
PCT/US2005/035257
Other languages
French (fr)
Other versions
WO2006039532A2 (en
Inventor
Marina Braun
Willi Cawello
Eric B Foster
Thomas Lauterbach
Hans-Michael Wolff
Original Assignee
Schwarz Pharma Inc
Marina Braun
Willi Cawello
Eric B Foster
Thomas Lauterbach
Hans-Michael Wolff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma Inc, Marina Braun, Willi Cawello, Eric B Foster, Thomas Lauterbach, Hans-Michael Wolff filed Critical Schwarz Pharma Inc
Priority to EP05802679A priority Critical patent/EP1796610A4/en
Priority to JP2007534813A priority patent/JP2008514376A/en
Publication of WO2006039532A2 publication Critical patent/WO2006039532A2/en
Publication of WO2006039532A3 publication Critical patent/WO2006039532A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

The invention provides a transdermal therapeutic system (TTS) containing rotigotine as the active ingredient. The TTS is useful in the treatment of Parkinson’s Disease because it induces a pharmacokinetic profile where the rotigotine plasma level is high and stable.
PCT/US2005/035257 2004-09-29 2005-09-29 Transdermal therapeutic system for parkinson’s disease WO2006039532A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05802679A EP1796610A4 (en) 2004-09-29 2005-09-29 Transdermal therapeutic system for parkinson's disease
JP2007534813A JP2008514376A (en) 2004-09-29 2005-09-29 Transdermal therapeutic system for Parkinson's disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61376004P 2004-09-29 2004-09-29
US61376104P 2004-09-29 2004-09-29
US60/613,760 2004-09-29
US60/613,761 2004-09-29

Publications (2)

Publication Number Publication Date
WO2006039532A2 WO2006039532A2 (en) 2006-04-13
WO2006039532A3 true WO2006039532A3 (en) 2006-07-13

Family

ID=36143101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035257 WO2006039532A2 (en) 2004-09-29 2005-09-29 Transdermal therapeutic system for parkinson’s disease

Country Status (3)

Country Link
EP (1) EP1796610A4 (en)
JP (1) JP2008514376A (en)
WO (1) WO2006039532A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (en) 2003-12-24 2005-07-28 Schwarz Pharma Ag Use of substituted 2-aminotetralins for the preventive treatment of Parkinson's disease
DE102004014841B4 (en) 2004-03-24 2006-07-06 Schwarz Pharma Ag Use of rotigotine for the treatment and prevention of Parkinson-Plus syndrome
EP3111935A4 (en) 2014-02-27 2017-03-15 Medrx Co., Ltd. Pramipexole-containing transdermal patch for treatment of neurodegenerative disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US5840336A (en) * 1992-10-05 1998-11-24 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (en) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
US6448303B1 (en) * 2000-12-29 2002-09-10 National Starch And Chemical Investment Holding Corporation Hot melt adhesives for dermal application
SI1256340T1 (en) * 2001-05-08 2003-12-31 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
ES2204780T3 (en) * 2001-05-08 2004-05-01 Schwarz Pharma Ag TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE THAT INDUCES HIGH LEVELS OF ROTIGOTINE IN PLASMA.
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
DE10261696A1 (en) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885308A (en) * 1984-08-13 1989-12-05 Nelson Research & Development Co. Method and compositions for treatment of parkinsonism syndrome in mammals
US5840336A (en) * 1992-10-05 1998-11-24 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1796610A4 *

Also Published As

Publication number Publication date
EP1796610A4 (en) 2012-12-05
EP1796610A2 (en) 2007-06-20
JP2008514376A (en) 2008-05-08
WO2006039532A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
DE60233898D1 (en) TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON DISEASE WITH HIGH ROTIGOTINE PLASMAS MIRRORS
WO2005102338A8 (en) Method of treating neuropathic pain using a crth2 receptor antagonist
EP1848541A4 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
WO2006055511A3 (en) Stable tablet formulation of tetrahydrobiopterin
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
WO2005037824A3 (en) Method for the production of amino crotonyl compounds
TW200738228A (en) Neramexane modified release matrix tablet
EP1611880A3 (en) Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006060547A3 (en) Systems and methods for intra-oral drug delivery
HUP0401512A3 (en) Transdermal therapeutic system (tts) with fentanyl as active ingredient
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
AU2003242988A1 (en) Process for the preparation of the anti-cancer drug imatinib and its analogues
WO2005089728A3 (en) Means for transdermal administration of nicotine
WO2007030944A3 (en) Methods of cardioprotection using dichloroacetate in combination with an inotrope
WO2007044437A3 (en) Octanol formulations and methods of treatment using the same
GB0119012D0 (en) Transdermal delivery of drugs
GB2446341A (en) Method and system for transdermal drug delivery
WO2006039532A3 (en) Transdermal therapeutic system for parkinson’s disease
HK1120417A1 (en) Stable nanoparticle formulations
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
EP1967208A4 (en) THERAPEUTIC AGENT FOR SKIN OR SKIN REPAIR-PROMOTING AGENT COMPRISING GHRELIN, DERIVATIVE THEREOF OR SUBSTANCE CAPABLE OF ACTING ON GHS-R1a AS ACTIVE INGREDIENT

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005802679

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007534813

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005802679

Country of ref document: EP